drug · antibody
GP-2
Phase 3updated 6mo agoby $GLSI Greenwich LifeSciences, Inc.🔗 ChEMBL
Phase 3community read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 20 approved and 146 investigational indications.
targets
Vascular endothelial growth factor A, long form
all catalysts(0)
nothing on the calendar yet
Trials studying GP-2
News(10)
- ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer raceIncyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.fiercebiotech · 25d ago
- ESMO: Zentalis already dreaming of launch for WEE1 inhibitor after ‘great result’ in early-stage testZentalis Pharmaceuticals has pointed to the first overall survival (OS) analysis for azenosertib as proof that the oral WEE1 tyrosine kinase inhibitor can offer a convenient oral treatment for a tr…fiercebiotech · 28d ago
- ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the futureWhen recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.fiercebiotech · 1mo ago
- Roche pens backloaded $2B deal with Atavistik to discover allosteric CVRM drugsRoche has penned a backloaded $2 billion deal with hematology biotech Atavistik Bio to develop allosteric small molecules for cardiometabolic diseases.fiercebiotech · 1mo ago
- Akeso CEO looks beyond lung cancer with biliary tract win, counters ivonescimab debateFresh off a phase 3 win in biliary tract cancer, Akeso CEO Michelle Xia, Ph.D., is touting the PD-1xVEGF bispecific antibody ivonescimab’s ability beyond non-small cell lung cancer, even as she con…fiercebiotech · 2mo ago
- TME holds onto $1B dream for brain cancer drug as search for partners nears conclusionTME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings to its hope of generating $1 billion in peak sales from the asset.fiercebiotech · 2mo ago
- Vaderis hauls in $152M to test an AKT-targeting drugThe startup is one of at least a few young companies zeroing in on the rare bleeding disorder, hereditary hemorrhagic telangiectasia, with a more precise AKT blocker.biopharma_dive · 3mo ago
- FDA scientists question Capricor data; Legend CEO steps downCapricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipe…biopharma_dive · 3mo ago
- Five Under 5: Top Oncology Videos for the Week of 5/3The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.onclive · 6mo ago
- Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROCAlexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.onclive · 6mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that